Login
$NVCR
$11.30 -$0.53 (4.48%) Live

$NVCR SEC Filings

Filed On Filing
12 Nov 2026 Form 4: Paravasthu Mukund, Chief Operating Officer

Sold 3,079 shares ($39.6K)

12 Nov 2026 Form 4: Brackmann Christoph, Chief Financial Officer

Sold 7,343 shares ($94.4K)

09 Nov 2026 SCHEDULE 13G/A
09 Nov 2026 144
09 Nov 2026 8-K: Regulation FD Disclosure

Novocure Provides Regulatory Update on U.S. FDA Premarket Approval Application for Optune Mya® for Brain Metastases from Non-Small Cell Lung Cancer

04 Nov 2026 Form 4: Puri Michal Nath, Chief Human Resources Officer

Sold 660 shares ($8.74K)

29 Oct 2026 S-8
29 Oct 2026 8-K: Results of Operations and Financial Condition

Third quarter net revenues of $193 million an increase of 16% year-over-year, driven by 19% growth in active patients worldwide

29 Oct 2026 10-Q
01 Oct 2026 8-K: Regulation FD Disclosure

Baar, Switzerland – October 1, 2026 – Novocure (Nasdaq: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnosed with unresectable locally advance...

09 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

(b) Timothy Scannell, a current director of NovoCure Limited (the “Company”), has retired from the Board and his seat was formally vacated pursuant to the Company’s Articles of Association effective September 2, 2026. Mr. Scannell's reti...

01 Sep 2026 8-K: Other Events

In mid-August 2026, NovoCure Limited (the "Company," "we," or "us") through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the unauthorized access, the Company activated its cybersecu...

23 Jul 2026 144
23 Jul 2026 8-K: Results of Operations and Financial Condition

Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications

23 Jul 2026 10-Q
01 Jul 2026 Form 4: Puri Michal Nath, Chief Human Resources Officer

Received 1,905 shares as a grant or award ($21.2K)

01 Jul 2026 Form 4: Leonard Frank X, Chief Executive Officer

Received 1,905 shares as a grant or award ($21.2K)

01 Jul 2026 Form 4: Ben Arye Barak, General Counsel

Received 1,299 shares as a grant or award ($14.5K)

01 Jul 2026 Form 4: Danziger Asaf, Director

Received 268 shares as a grant or award ($2.99K)

30 Jun 2026 8-K: Regulation FD Disclosure

The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support